CLINICAL TRIALS PROFILE FOR CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00968812 ↗ | CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride | Completed | Janssen Research & Development, LLC | Phase 3 | 2009-09-01 | The purpose of this study is to demonstrate the efficacy, safety, and tolerability of canagliflozin (JNJ-28431754) compared with glimepiride in patients with type 2 diabetes mellitus with inadequate control despite treatment with metformin. |
| NCT01081834 ↗ | The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial | Completed | Janssen Research & Development, LLC | Phase 3 | 2010-03-01 | The purpose of this study is to evaluate the efficacy, safety, and tolerability of 2 different doses of canagliflozin administered as monotherapy compared with placebo in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with diet and exercise. |
| NCT01106625 ↗ | The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea) | Completed | Janssen Research & Development, LLC | Phase 3 | 2010-05-01 | The purpose of this study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in patients with type 2 diabetes mellitus who are receiving treatment with metformin and sulphonylurea and have inadequate glycemic (blood sugar) control. |
| NCT01106677 ↗ | The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial) | Completed | Janssen Research & Development, LLC | Phase 3 | 2010-05-01 | The purpose of this study is to evaluate the efficacy and safety of canagliflozin compared with sitagliptin and placebo in patients with type 2 diabetes mellitus who are receiving treatment with metformin monotherapy (i.e., treatment with a single drug) and have inadequate glycemic (blood sugar) control. |
| NCT01106690 ↗ | The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone) | Completed | Janssen Research & Development, LLC | Phase 3 | 2010-06-01 | The purpose of this study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in patients with type 2 diabetes mellitus who are receving treatment with metformin and pioglitazone and have inadequate glycemic (blood sugar) control. |
| NCT01137812 ↗ | The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial) | Completed | Janssen Research & Development, LLC | Phase 3 | 2010-07-01 | The purpose of this study is to evaluate the efficacy and safety of canagliflozin compared with sitagliptin in patients with type 2 diabetes mellitus who are receiving treatment with metformin and sulphonylurea and have inadequate glycemic (blood sugar) control. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE
Condition Name
Clinical Trial Locations for CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE
Trials by Country
Clinical Trial Progress for CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE
Clinical Trial Phase
Clinical Trial Sponsors for CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE
Sponsor Name
| Sponsor Name for CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE | |
| Sponsor | Trials |
| Janssen Research & Development, LLC | 31 |
| Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 5 |
| University of Leicester | 2 |
| [disabled in preview] | 3 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
